Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%
Telix Pharmaceuticals (ASX:TLX) reaching alignment with the US Food and Drug Administration (FDA) to advance a phase 3 trial of its TLX591-Tx therapeutic candidate is in line with expectations, according to a Thursday Jefferies note. The company said on Thursday that the US regulator confirmed that safety data from part one of the study is adequate to allow for the progression of part two. Jefferies added that the update results in no changes to forecasts or the price target for Telix Pharmaceuticals. Jefferies kept a buy rating on Telix with a price target of AU$27.40. The company's shares fell 3% in recent Friday trade.
Telix Pharmaceuticals (ASX:TLX) reaching alignment with the US Food and Drug Administration (FDA) to advance a phase 3 trial of its TLX591-Tx therapeutic candidate is in line with expectations, according to a Thursday Jefferies note.
The company said on Thursday that the US regulator confirmed that safety data from part one of the study is adequate to allow for the progression of part two.
Jefferies added that the update results in no changes to forecasts or the price target for Telix Pharmaceuticals.
Jefferies kept a buy rating on Telix with a price target of AU$27.40.
The company's shares fell 3% in recent Friday trade.